Finally, for 22 COVID-19 patients of R group, a further evaluation of sCD163 plasmatic levels was performed at T45 showing a significant reduction compared to T0 (T0: 1179 [812-1412], T7: 868 [588-1141] and T45: 807 [486-1059], p=0.0475). This evidence concerns the gene CD163 and COVID-19.